Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021253 | 0.90 | BCHE (1.00) | BCHECARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL4026157 | 0.86 | BCHE (1.00) | BCHE | |
| SCHEMBL4022404 | 0.83 | BCHE (1.00) | BCHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL4028855 | 0.80 | BCHE (1.00) | BCHECARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL4027386 | 0.79 | BCHE (1.00) | BCHECARM1PRMT6PRMT8 | |
| SCHEMBL4022974 | 0.77 | BCHE (0.64) | BCHECARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL4025061 | 0.77 | BCHE (0.64) | BCHECARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL4020282 | 0.76 | BCHE (1.00) | BCHE | |
| Oxalic Acid SCHEMBL7322850 | 0.76 | BCHE (0.62) | BCHECARM1PRMT6TMEM97SIGMAR1 | |
| SCHEMBL9786843 | 0.75 | BCHE (0.60) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446400-B1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2009-01-28 | — | — | EP | claimed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | claimed |
| EP-1446400-A4 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2005-06-01 | — | — | EP | claimed |
| US-20050043316-A1 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2005-02-24 | — | — | US | claimed |
| EP-1446400-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC Nara Co. Ltd. (KR) | 2004-08-18 | — | — | EP | claimed |
| WO-2003033489-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO., LTD. (KR) | 2003-04-24 | — | — | WO | claimed |
| EP-1446400-B1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2009-01-28 | — | — | EP | disclosed |
| EP-1446400-B1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2009-01-28 | — | — | EP | disclosed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | disclosed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | disclosed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | disclosed |
| EP-1446400-A4 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20050043316-A1 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2005-02-24 | — | — | US | disclosed |
| EP-1446400-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC Nara Co. Ltd. (KR) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003033489-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO., LTD. (KR) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043316-A1 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | APP, ACHE, PSEN1 | BCHE 7/4885LMNA 1927/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.